Key result
Lowering the platelet count within the normal range using a thrombopoietin inhibitor reduced experimental occlusive thrombogenesis on collagen-coated vascular grafts in baboons without impairing hemostasis.
Why the study?
Does moderate platelet count reduction by thrombopoietin inhibition reduce experimental occlusive thrombogenesis without impairing hemostasis in baboons?
Does moderate platelet count reduction by thrombopoietin inhibition reduce experimental occlusive thrombogenesis without impairing hemostasis in baboons?
Suppressing platelet production to moderately lower platelet counts within the normal range reduces thrombogenesis without impairing hemostasis in primates, offering a potential novel antithrombotic strategy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for moderate platelet reduction as antithrombotic strategy; leaves open translation to human thrombotic disease.
Most heart attacks and strokes are caused by blood clots (thrombi) that block the vasculature. Because disease-causing arterial thrombosis depends on blood platelets, platelet inhibitors such as aspirin and clopidogrel effectively decrease the risk of thrombosis; however, they also impair platelet-dependent hemostasis that staunches bleeding from wounds and can therefore produce excessive bleeding. Experimental studies show that a reduction in the number of platelets also inhibits thrombosis, but these treatments also interfere with platelet function. Because normal hemostasis requires that the platelet concentration remain within a physiological range in the circulation, we evaluated whether lowering the number of circulating platelets--but only to a value still within the normal range--by inhibiting platelet formation in the bone marrow inhibits acute thrombogenesis in baboons. We reduced the platelet count with an inhibitor against the megakaryocyte-promoting hormone thrombopoietin and then showed that experimental occlusive thrombogenesis on collagen-coated vascular grafts was reduced, without impairment of primary hemostasis. These results suggest that suppressing platelet production without interfering with the hemostatic function of platelets may offer a safe alternative to current therapies for prevention of stroke and heart attack triggered by blood clotting.
No takes yet. Share an insight, caveat, or question.
Tucker et al. (2010) studied Thrombosis. Thrombopoietin inhibitor was evaluated on Experimental occlusive thrombogenesis on collagen-coated vascular grafts. Lowering the platelet count within the normal range using a thrombopoietin inhibitor reduced experimental occlusive thrombogenesis on collagen-coated vascular grafts in baboons without impairing hemostasis.
Synapse has enriched 10 related papers. Consider them for comparative context: